Hyperfibrinolysis in hepatosplenic schistosomiasis

Journal of Clinical Pathology

Volumn 49, Issue 12, 1996, Pages 990-993

  El Bassiouni, N E ^a   El Bassiouny, A E ^b   El Khayat, H R ^b   Akl, M M ^b   Omran, S A ^a  

^a Imbaba   (Egypt)

^b Department of Immunology ^*

Author keywords

Fibrinolytic activity; Haematemesis; Hepatosplenic schistosomiasis; Hyperfibrinolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEPATOSPLENOMEGALY; HUMAN; MALE; PHOTOMETRY; PRIORITY JOURNAL; SCHISTOSOMIASIS;

EID: 0030427070     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.12.990     Document Type: Article

References (38)

1. Zakaria S, Thakeb F, Labib S, El-Sahly A, Hunter S, El-Rooby A. Incidence of oesophageal varices as a cause of upper gastrointestinal bleeding among patients subjected to upper gastrointestinal endoscopy. In: Zakaria S, Thakeb F, eds. Gastrointestinal endoscopy: an Egyptian view. Cairo, Egypt: Nidoc Publications 1988:3-11.
2. Omran SA, Madkour BA, Essawy FM, Toima SA, El-Kaliouby AH, Shams El-Din AA. The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis. Blood Coag Fibrinol 1992;3:819-22.
3. Omran SA, El-Bassiouni NE, Amer AM, Hussein AT. Fibrinolytic parameters during acute hematemesis in endemic hepatosplenomegaly. Blood Coag Fibrinol 1993;4:891-4.
4. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992;15:672-6.
5. Bertaglia E, Belmonte P, Vertolli U, Azzurro M, Martines D. Bleeding in cirrhotic patients: A precipitation factor due to intravascular coagulation or to hepatic failure? Haemostasis 1983;13:328-34.
6. Francis RB, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984;14:460-5.
7. Boks AL, Brammer EJP, Schalm SW, Van Vliet HHDM. Haemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986;6:79-86.
8. Leebeek FWG, Kluft C, Knot EAR, De Maat MPM, Wilson JHP. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991;101:1382-90.
9. Aoki N, Yamanaka T. The alpha-2 plasmin inhibitor levels in liver disease. Clin Chim Acta 1978;84:99-105.
10. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: Demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984;37: 772-7.
11. Hersch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor. Blood 1987;69: 1315-19.
12. Omran SA, El-Bassiouni NE, Hussein NA, Akl MM, Hussein AT, Ahmed AM. Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. Haemostasis 1995;25:218-28.
13. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietronic MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
14. Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981;1:673-6.
15. Clauss A. A rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-40.
16. Kluft C. Studies on the fibrinolytic system in human plasma: Quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979;41:365-83.
17. Stief IW, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: A novel principle. Thromb Res 1988;50:559-73.
18. Silverstein RM. The determination of human plasminogen using N(A) CB2-L. Lysine Paranitrophenyl ester as substrate. Anal Biochem 1975;65:500-6.
19. Teger-Nilsson AC, Friberger P, Gyzander E. Determination of new rapid plasmin inhibitor in human blood by means of a plasma specific tripeptide substrate. Scand J Clin Lab Invest 1977;37:403-9.
20. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985;54:684-7.
21. Amiral J, Plassart V, Contant G, Guyader AM. Different methods for the determination of tissue plasminogen activator (tPA) and of its inhibitor (PAI). J Clin Lab Inst Reagents 1990;13:599-610.
22. 2-antiplasmin inhibitor-plasmin complex determination in human plasma. Fibrinolysis 1992;6 (Suppl 3):94-6.
23. Koppert PW, Koopman J, Haverkate F, Nieuwenhuizen W. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising Bβ 54-118) in degradation products of fibrin and of fibrinogen. Blood 1986;68:437-41.
24. Koppert PW, Hoegee-de Nobel E, Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemost 1988;59:310-15.
25. Soria J, Soria C, Boucheix C, Mirshahi M, Perrot JY, Bernadou A, et al. Monoclonal antibodies that react preferentially with fibrinogen degradation products or with cross-linked fibrin split products. Ann N Y Acad Sci 1983; 408:665-6.
26. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101-6.
27. Pelzer H, Schwarz A, Stuber W. Determination of human pro thrombin activation fragment F 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153-9.
28. 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. Br J Haematol 1984;56:545-56.
29. Savion N, Farzama N. Binding uptake and degradation of antithrombin III-proteases complexes by cultured corneal endothelial cells. Exp Cell Res 1984;153:50-60.
30. Leiper K, Booth NA, Reith A, Moore NR, Bennett B. Plasminogen activator inhibitors (PAI-1, PAI-2) and t-PA-PAI-1 complex in liver disease (abstract). Fibrinolysis 1990; 4(Suppl 3):150.
31. Booth NA, Anderson JA, Benett B. Plasminogen activator in alcoholic cirrhosis: Demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984;37:772-7.
32. Takahashi H, Tatewaki W, Wada K, Yoshikawa A, Shibata A. Thrombin and plasmin generation in patients with liver disease. Am J Hematol 1989;32:30-5.
33. Fitch P, Bennett B, Booth NA, Croll A, Ewen SWB. Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases. J Clin Pathol 1994; 47:218-21.
34. Sufferedini AF, Harpel PC, Parrilo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320:1165-72.
35. Amer AM, El Defrawi IE, El Sherif NH, El Khayat HR. Is the coagulopathy of hepatosplenic schistosomiasis immune-related? Blood Coag Fibrinol 1994;5:789-93.
36. Sprengers ED, Prince HGM, Kooistra T, Hinsbergh VWM. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985;105:751-8.
37. Fujii S, Lucore CL, Sobel BE. Induction of endothelial cell synthesis of plasminogen activator inhibitor by t-PA. Circulation 1989;80(Suppl 2):111-15.
38. Rijken DC, van Hinsbergh VWM, Sens EHC. Quantitation of tissue type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res 1984;33:145-53.